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Abstract
Background: Saliva is an enriched milieu containing biologically active proteins, including growth
factors and cytokines. The endothelial growth factor family of proteins is important for the
development of blood and lymphatic vessels in a healthy individual but also can aide tumour growth.
The aim of this study is to develop an independent normative database of values of salivary VEGF
in a healthy population and to test the hypothesis that values would be raised in the saliva of
patients with oral cancer.
Methods: Twenty-one participants (12 males and 9 females) of whom 14 were healthy and 7 had
oral squamous cell carcinoma took part in this study.
An immunoassay was employed to quantify a range of specific vascular endothelial and lymphatic
endothelial growth factors in various body fluid compartments (blood, saliva). This was correlated
to tumour factors and patient outcomes.
Results: The mean salivary levels and serum VEGF A165 levels were significantly correlated in the
sample as a whole. Additionally, both saliva and serum VEGF A165 levels were significantly
correlated with age. There were significant differences in the salivary and serum levels of the
control group and the cancer group.
Conclusion: We present independent normative data on the levels of endothelial growth factor
in the saliva of a healthy control population. We also suggest the use of simple non-invasive tests
in helping to predict head and neck tumour biology and outcomes.
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Background
Saliva is an enriched milieu containing biologically active
proteins, including growth factors and cytokines [1]. The
endothelial growth factor family of proteins is important
for the development of blood and lymphatic vessels in a
healthy individual but can also aide tumour growth. Head
and neck cancers are known to secrete high levels of
endothelial growth factors which may aid their growth
(angiogenesis) and metastasis (lymphangiogensis).
Vascular endothelial growth factor (VEGF or VEGF-A),
also known as vascular permeability factor (VPF), is
known for its important roles in regulating both physio-
logical and pathological blood vessel growth. It is a mem-
ber of the VEGF family that also includes VEGF-B, -C, -D,
-E, and PlGF (placental growth factor). VEGF165 appears
to be the most abundant isoform.
VEGF transcription is potentiated in response to hypoxia,
oncogenic transformation, and growth factors. Upregula-
tion of VEGF during conditions of low oxygen tension is
dependent upon the activities of the hypoxia-inducible
transcription factors Hif-1 and Hif-2. VEGF is a potent
endothelial cell mitogen that can activate phospholipase
C and induce rapid increases of free cytosolic Ca2+. VEGF
has been shown to stimulate von Willebrand factor
release from endothelial cells and induce expression of tis-
sue factor in endothelial cells and monocytes. VEGF has
also been shown to be chemotactic for monocytes and
osteoblasts [2].
In vivo, VEGF can induce angiogenesis and increase micro-
vascular permeability. As a vascular permeability factor,
VEGF acts directly on the endothelium and does not
degranulate mast cells. It promotes extravasation of
plasma fibrinogen, leading to fibrin deposition which
alters the tumor extracellular matrix. The modified extra-
cellular matrix subsequently promotes the migration of
macrophages, fibroblasts and endothelial cells. Based on
its in vitro and in vivo properties, VEGF is expected to play
important roles in inflammation and normal and patho-
logical angiogenesis, a process that is associated with
wound healing, embryonic development, and growth and
metastasis of solid tumors [2,3].
Saliva is a known source of VEGF. The existence of a "sal-
ivary VEGF system" suggests that salivary VEGF plays a
role in regulating physiologic and pathologic angiogenic
and other vascular responses in salivary and mucosal tis-
sues. In particular, the presence of VEGF in saliva may
contribute to the remarkable healing capacity of the oral
mucosa as well as other regions of the digestive tract [1].
The presence of considerable quantities of VEGF in nor-
mal human saliva suggests an important role for this
cytokine in the maintenance of mucous membrane home-
ostasis. Rapid induction of neoangiogenesis by salivary
VEGF helps accelerate the wound healing within the oral
cavity. Moreover, salivary VEGF may permeabilize intrag-
landular capillaries and thus participate in the regulation
of saliva production itself [3]. VEGF could be relevant to
angiogenic processes in healthy as well as diseased perio-
dontal tissue and that the periodontal status influences
the salivary level of VEGF [4].
Many head and neck cancers are aerodigestive in origin,
with the initial tumour developing from the epidermis
exposed to carcinogenic agents. As the epidermal tumour
develops the surface integrity is interrupted with exposure
of the tumour to the digestive tract. The mucosal surface
of these tumours is in direct contact with saliva and upper
respiratory tract secretions and may contribute to salivary
VEGF. Furthermore, tumour cells may secrete VEGF in an
autocrine and paracrine fashion. It is hypothesized that
the salivary VEGF content of these patients may yield as
much prognostic information about the primary tumour
as the serum VEGF. This would avoid the effects of other
sources of VEGF such as tissue or blood factors. However
the ulcerated acute and chronic inflammatory processes
with superimposed infection and immune responses gives
an elevated VEGF level that is not correlated just with the
tumour but with the effects of the ulcerated and infected
mucosa. This may be in itself pro-carcinogenic. Salivary
VEGF levels seem to be associated with ulcer development
in major recurrent aphthous ulceration [5,6].
Following the paucity of publications found during
PubMed & Medline search using the key words "saliva",
"VEGF2 and "cancer", we present the first independent
normative database of values of salivary VEGF in a healthy
population and test the hypothesis that values may be
raised in the saliva of patients with oral cancer.
Materials and methods
Twenty-one participants (12 males and 9 females) of
whom 14 were healthy and 7 had oral squamous cell car-
cinoma (OSCC) took part in this study at the Royal
National Throat, Nose & Ear Hospital and the Eastman
Dental Hospital, London; the gender proportion in each
group was similar with a mean age of 33.57 years. The
protocol was approved by the Local Committee of the
Ethics for Human Research.
An information sheet explaining the aim of our study in
simple non-scientific terms was given to each of the
patients. Each patient was asked to sign a consent form
prior to the trial.
An immunoassay was then employed to quantify a range
of specific vascular endothelial and lymphatic endothelialInternational Archives of Medicine 2009, 2:12 http://www.intarchmed.com/content/2/1/12
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growth factors in various body fluid compartments
(blood, saliva).
The subjects were asked to adequately hydrate in the 24
hours prior to sampling. Dehydrating agents such as caf-
feine and alcohol were avoided. Subjects were asked to
swill out their oral cavity with water before whole saliva
was collected using an AccuSorb™ (without enzyme bind-
ing or filtering capabilities) and assays were performed
immediately. Serum was collected from venous puncture
and the sample placed in a serum separator tube and
allowed to clot for 30 minutes before centrifugation for 15
minutes at approximately 1000 × g. The serum was then
assayed immediately.
VEGF165 was considered in particular since it is the most
known and studied isoform in the current literature. We
used the R&D Systems Human VEGF Immunoassay,
QuantiGlo Human VEGF Immunoassay (Catalog
Number QVE00B). The QuantiGlo Chemiluminescent
VEGF Immunoassay is a 5.5 hour solid phase ELISA
designed to measure VEGF165 levels in serum and saliva.
This assay employs the quantitative sandwich enzyme
immunoassay technique. A monoclonal antibody specific
for VEGF has been pre-coated onto a microplate. Stand-
ards and samples were pipetted into the wells and any
VEGF present was bound by the immobilized antibody.
After washing away any unbound substances, an enzyme-
linked polyclonal antibody specific for VEGF was added
to the wells. Following a wash to remove any unbound
antibody-enzyme reagent, an enhanced luminol/peroxide
substrate solution was added to the wells and light was
produced in proportion to the amount of VEGF bound in
the initial step. A microplate luminometer (Specta Max
340 pc Molecular devices microplate reader) was used to
measure the intensity of the light emitted. All samples
were analysed in triplicate in independent experiments
and representative data presented.
Statistical analysis
Differences between groups were tested using the c2 test
for frequency data and ANOVA/ANCOVA/Mann Whitney
U Tests for continuous data. Where appropriate, measures
of the strength of association between variables were pro-
vided through Cramer's phi (fc) and omega squared (ω2);
add in interpretations guidelines for r2 & ω2. Associations
between variables were examined using Pearson's correla-
tion coefficient, with the coefficient of determination (r2)
as a measure of the strength of association. Significance
levels for all tests were set at p < 0.05.
Results
A direct correlation was made with T stage and N stage of
OSCC patients and the levels of detectable endothelial
growth factor. The effect of surgery was also determined.
There were 12 males and 9 females, with differing gender
proportions in each group (Fisher's exact test p = 0.642;
Φc = 0.204; control 7 male, 7 female: cancer 5 male 2
female OR although violation of assumption 2 = 0.875, df
= 1, p = 0.350; Φc = 0.204). The mean age of the sample
was 33.57 years (sd = 11.31), with the control group
(mean = 28.714, sd = 10.126) significantly younger than
the cancer group (mean = 43.286, sd = 6.264; F(1,19) =
12.004, p = 0.003, ω2 = 0.344).
Mean individual specific saliva levels and serum VEGF
A165  levels were significantly correlated (Pearson's r =
0.653, p = 0.001, r2 = 0.426), in the sample as a whole.
The same relationship was calculated for each group sep-
arately (control: Pearson's r = 0.424, p = 0.131, r2 = 0.180;
cancer: Pearson's r = -0.533, p = 0.198, r2 = 0.284) and did
not significantly differ between the groups (z = 1.842, p =
0.066). Additionally, both saliva (Pearson's r = 0.584, p =
0.005, r2 = 0.341) and serum VEGF A165 levels (Pearson's
r = 0.467, p = 0.033, r2 = 0.218) were significantly corre-
lated with age (Figure 1).
The Mann-Whitney U test revealed significant differences:
in the serum levels (U = 0, p < 0.001) of the control group
(mean rank = 7.5) and the cancer group (mean rank =
18.0); and the saliva levels (U = 0, p < 0.001) of the con-
trol group (mean rank = 7.5) and the cancer group (mean
rank = 18.0).
Furthermore, ANCOVAs examining treatment group dif-
ferences revealed significant group effects on the serum
measure (F(1,18) = 58.222, p < 0.001, ω2 = 0.337) after
controlling for age (F(1,18) = 0.027, p = 0.871, ω2  ≈
0.000), with the control group serum levels (mean =
Graph of Serum and Salivary VEGF A165 levels in control sub- jects and cancer patients Figure 1
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1391.971 pg/ml, std. error = 199.364) significantly lower
than the cancer group's (mean = 4451.005 pg/ml, std.
error = 305.484); and significant group effects on the
saliva measure (F(1,18) = 16.018, p = 0.001, ω2 = 0.491)
after controlling for age (F(1,18) = 0.006, p = 0.938, ω2 ≈
0.000), with the control group saliva levels (mean =
231.609 pg/ml, std. error = 113.970) significantly lower
than the cancer group's (mean = 1148.875 pg/ml, std.
error = 174.636). The homogeneity of regression slopes
assumption was not violated in either analysis (Figure 1).
Discussion
We present an independent normative data on the levels
of endothelial growth factor in the saliva of a healthy con-
trol population. We also suggest the use of simple non-
invasive tests in helping to predict head and neck tumour
biology and outcomes [2-4].
The mean saliva levels and serum VEGF A165 levels were
significantly correlated in the sample as a whole. Addi-
tionally, both saliva and serum VEGF A165 levels were sig-
nificantly correlated with age. There were significant
differences in the salivary and serum levels of the control
group and the cancer group. Further, we found significant
group effects on the salivary and serum measures of VEGF
A165 after controlling for age with the control group sali-
vary and serum levels significantly lower than the cancer
group. Variations in the females of the control group were
accounted for by the increased angiogenic activity during
menstruation [7]. Differences between the control and
cancer groups could not be accounted for by simple differ-
ences in gender proportions or age. We are collecting data
on the group effects on the salivary and serum measures
of VEGF A165 after controlling for age and gender.
Blood VEGF A165 was a good predictor of disease state [2-
4] and the effect of surgery, however blood VEGF assess-
ment is still an invasive test.
Salivary VEGF A165 is also an indicator of tumour burden
and may possibly be employed as a non-invasive test. Its
utility as a relatively inexpensive screening test for oral
cavity cancer awaits larger multi-centered studies. The rel-
evance of this pilot study lies in its possible development
as a prognostic test with utility in the development of an
effective prevention program to control head and neck
cancer [8]. When compared with other highly diagnostic
salivary tumour biomarkers, the advantages of this simple
ELISA over the laboratory based 'in vitro detection of cyto-
toxic effects of saliva by using the plating efficiency index'
[9] lie mainly in the ease of collection, simplicity of use
and speed of results of the former. Despite this both tests
have significant merit and may in fact be complementary.
In conclusion saliva appears to provide a rich source of
information regarding the epithelium, especially during
neoplastic transformation.
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